Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.69 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415759 | 1.00 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRHIF1AEPAS1 | |
| SCHEMBL12415757 | 0.91 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL12415738 | 0.91 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL12415742 | 0.91 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL12415746 | 0.91 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL12415741 | 0.91 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL12415739 | 0.91 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL12415745 | 0.91 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL12415740 | 0.91 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL12415736 | 0.91 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | GB005, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH4 | PTGDR2 87/4885TBXA2R 115/4885PTGDR 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.